Video

Relapsed/Refractory myeloma | Rebecca Silbermann, MD

Posted by
HealthTree Logo HealthTree
• November 27, 2026

Description

In this interactive breakout session from the HealthTree Portland Myeloma Roundtable (November 7, 2026), Rebecca Silbermann, MD, MMS of OHSU Knight Cancer Institute guides newly diagnosed multiple myeloma patients and caregivers through early treatment decisions and answers live audience questions.

Key topics covered in this session:

• Understanding your initial multiple myeloma diagnosis, staging, and genetic risk factors

• Navigating frontline induction therapies, stem cell transplant eligibility, and maintenance options

• Managing early side effects and building a strong partnership with your myeloma care team

Timestamps:

0:00 Maintenance Decisions & Trial Timelines

3:44 Patient Advocacy With Your Doctor

9:14 Choosing Among Treatment Options

12:05 Defining a Myeloma Cure

15:30 Genomic Testing for Treatment Choices

18:56 clonoSEQ & Ordering MRD Tests

21:19 Interpreting MRD and PET Results

26:03 PET Versus PET-MRI Imaging

28:07 Peripheral Blood MRD Testing

29:16 Monitoring Frequency After Remission

Event details: https://healthtree.org/events/portlandrt2026

Transcript

though. More about Charles. That's a. Big. So long as it comes, this one has to be applied like in terms of maintenance or activities. Trials are going on. They can take forever in the sense that time. And so maybe the meantime there should be some judgment applied. Continue maintenance or not continue meetings. Seems like the trials get it seems to me that should be part of the evidence or solution, not the at the end all in terms of what the decision was made. I just, I mean, yeah, I guess I agree with you. I think it's tricky. Right? We've got to find a balance point. We have to think about safety. We have to think about regulations. We have to think about, interpreting data appropriately, particularly if you're thinking about adding a new medication or taking away a medication, because sometimes a signal that you might have that says that something is good or bad is not going to be fully realized until a trial has accrued. But I think that you're right. The pace of, more formalized clinical trial programs is slow, given how quickly medications are being developed and how quickly the field has been changing. So your point is well taken. I think that in many academic centers, we have the luxury of having a little bit more time to think great thoughts, supposedly, and to like, consider what we think in the context of what is the approved indications for treatment. And that's how we make some progress. You know, we think these thoughts and then we talk to our colleagues about our thoughts, and then we get together and maybe we try to design a trial that'll be more efficient and that'll be asking the right questions of our perspective. It's super frustrating also that the trials that we think are asking the best questions, the most impactful questions are likely not going to read out for decades, at which point the answer may or may not be relevant anymore. It was so if somebody said, okay, we did a trial with a cigarette, smoking is bad. I would get in the way of good medicine in terms of be able to use judgment and reasoning to see a painting, a decision that having a good idea to stop smoking even though there's no trial. But totally the other example is the best method on problem, right? There's never going to be a trial that's going to say, what is the minimal amount of dex that you actually need to get some benefit? In my alone studies, no one's going to pay for that trial. We just are going off of experience that the amount of dex that we use, even though it's 25% of what we used to use, is still too much and probably too much for everybody. And so we do the best we can at dose adjustments to hide the right, the right level for. I want to talk about patient advocacy with the doctor and kind of in relation to what we were just talking about here, rather than waiting for the official word, the standard of care. How does it best work to sit down and have that discussion with your doctor and say, I get that standard of care in my situation? What if we do, for example, treatment for surveillance? Because I've been here for x amount of time, had because my sense is that the doctor is constrained to some degree by what the protocols are with standard of care is how does a patient help to be able to move beyond that in their own situation? Really great question. It's hard. It's really difficult. I think that yes, there are circumstances where the physician is constrained by what their organization or what the insurance carriers will allow them to prescribe. But I also think that there is a power imbalance that needs to be acknowledged. I don't know that it's a bad thing entirely, but I think that you, as a patient, going into a room with a physician, are in a different place. And if you were having a chat at a coffee shop, that is kind of how we've set things up in medicine for a long time. So I think one portion of your question is, how do I even ask the questions of my physician? How do I even say, hey, I really you know, I'm putting words in the person's health. I appreciate the care that I've received so far, but I've been reading about some stuff and I've been thinking about some things. I'm curious about what you think about these sorts of things. That's hard. That's a really hard conversation. And I think that there's a personality component to it. Some people are just not going to feel like that kind of conversation with you. Right? It there's a logistic east to it from the patient's perspective. I don't know if you would know that a physician might be limited by organizational rules unless you specifically asked. I don't practice. The example I have is Kaiser, right. I don't practice Kaiser. I don't know what it means to be a Kaiser physician who wants to tell my patient about something that may not be available at Kaiser. I don't know what the guidebook is that that Kaiser practitioners are given in those circumstances. I know that there are mechanisms to allow Kaiser physicians to offer treatments that aren't available at Kaiser under certain circumstances, but I don't know how you get there. I think you have a follow up because you're hoping I do. I'm trying to figure out what how can we make it easier in the doctor to have these conversations? And I'm thinking of a specific example, of the protocol around maintenance. I mean, when I came into treatment, it was your maintenance room, and that's, thank God, starting to get some scrutiny. Is that really necessary? And those protocols were developed at a time when we didn't have ten, 26 best that we can hope for. Spending money was five. And now we know so much more. We've got, mechanisms that can give us better information. And so it becomes a point where if there's a protocol or even standard of care, which I don't understand, is actually a legal term which is important in medicine. But going back to how can we approach doctors and make it easier for them to be able to say yes or yeah, let's talk about that. Yes. I think, this is just an opinion suggestion. I think I would say that you should tell the doctor that you want to have the conversation and say, when would it be a reasonable time for us to do that? So this isn't something you bring up as they're heading out the door after you've talked about your rash. Right. This is a separate this is a separate conversation. This isn't something that you address by attaching a multi-page PDF file to your MyChart message. Right. This is something different. This is a separate conversation, and I think that it is reasonable to ask if they'd be open to the conversation. And if they're not open to it, that's okay. You say, how would you suggest I get this information? And maybe it's that you get another opinion somewhere else. Maybe it's that you get a in person versus a video opinion. There's ways to get other types of written opinions if there's financial resources available. But I just laid on the table. So you want to talk about it. You want to know what what's possible. Yeah. Mary Rose usurps several of my questions on that. But the, there's you mentioned standard of care in the tech industry. We say the great thing about standards is there's so many to choose from, and it seems like that applies here as well. Once you get beyond that for drug induction, standard of care almost goes out the window. Whether you go on maintenance or whether you go to transplant or whether you party and all that other stuff. You know what? And then you've got zillions of clinical trials available to you as a as a provider and also as a patient. How do we know what's the best next step for us? I don't know if this is a comforting answer or not, but it's honest. Last month we're not saying that this one, There really is probably not a right answer. There's a lot of ways to get to success, and we're learning that. I think there are some answers that are clearly the wrong answers for a particular human experiencing myeloma receiving certain treatments. We can definitely make people really sick, but I am not convinced that there is a one perfect answer that we're looking for in this whole list of possibilities that are out there. You're right, there are pretty clear algorithms saying this is how you start, and then it all opens up. And there's a lot of different choices out there. And it's one of the reasons that when I'm talking to the the trainees, the Heman Fellows, their eyes kind of get they get a look when we're talking about how myeloma is tricky because it is not a clear algorithm. You do this, then you do this, then you do this. It's a lot of nuance. So I think there has to be discussion about what is the individual patients goal. What is the likelihood that they would be able to tolerate a particular set of treatments or type of treatment? And then what else is going on in the world that is important for that patient and for their health care team to know about? So if they live, you know, in the high desert and don't drive, then a treatment that would require them to come into Portland twice a week is probably not possible. And so we have to couch whatever decision we make in the reality where that person is, is existed. Yeah. My understanding is that there's now talk about what a cure for myeloma would have to have. I'm wondering, can you talk about that? What is our people actually up here? Yes. That's what we're really supposed to be talking, and I just had to open it up to all the questions. There was a conference in the spring of last year in Florida, Miami, I think, where they brought together a lot of researchers, as well as people who are actively involved in caring for cancers that we commonly say that we can cure. We also had patient advocates. They had other community members, and they basically had a lot of conversation about what would cure mean in general. And then how would we potentially, use that term in the setting of myeloma? Some of this was inspired by the fact that the longer term follow up data on some of the studies demonstrates that people are enjoying years of time where their disease is quiet without any kind of treatment, without any maintenance, without anything specifically directed to myeloma. They may be getting supportive treatments like treatments to help keep their immune system healthy, but they're not getting myeloma treatment. And so if someone is going. Three years, four years, five years without needing any treatment, why can't we say that they are cured? So that's part of what prompted that conversation. The other piece is this acknowledgment that we do use the term cure in relation to other cancers. And we understand intellectually that cancers can still come back after they've been cured. So we probably shouldn't paint ourselves into a corner where we're saying our definition of cure is going to mean that it's never, ever, ever going to come back again. So with that background, they said, let's snip a little bit. Let's just take take some ideas. As for what cure could be defined as in myeloma? And the consensus that was put together was saying five years MRD negative, no treatment. And so a caveat to that, which is important to realize is that we talked or I talked a little bit about bone marrow based MRD assessment. I didn't say anything about imaging based assessment. And that's something to to acknowledge. Bone marrow MRD assessment is measured. What is in the needle when you get your bone marrow biopsy done? People can have plasmacytomas. They can have disease that is outside of the bone marrow, that is still myeloma. And you were going to miss that on a bone marrow. MRD assessment. So you have to do the primary in parallel with advanced imaging. That can take a good look to see what else is going on in the rest of the body. That's PET-CT or whole body MRI. Or if you're super fancy, you can do a PET MRI, but that takes a lot of doing with the orders of the. So more than the the more traditional X-rays, skeletal survey that we used to do after several men. First of all, thank you for being here today, giving us your Saturday. I think one of the things we all know is how we are able to be and genetically the different twist, the variations and how that might impact the treatment options of the success of those. And we're beginning to worry about things like Daniel, are those tools commonly in practice at academic centers, and how useful are they? Are we as patients, should we be asking for more genetic testing to help clarify and provide better treatment choices? I think that's a really good question, and I don't actually know the answer. It feels to me very similar to where we were sitting 4 or 5 years ago when, NGS for MRD testing was really getting going and we knew we could do the test. We knew we could get the answers from the test, but we didn't know what we were going to do with the data. So I very much remember saying probably out loud, which I should have done, that the me at that day was not getting it for all of my patients, but I was very sure that future me was going to be annoyed by that, because I was going to wish that I had been collecting that data. So I I'm with you, Gina. And then there's another similar style set of testing that can be done from a team in summer in California. It is so compelling and it is so interesting, and I am not sure whether it should be done or not done. We argue about this and our and our tumor board, and I'm usually the one saying, wouldn't it be cool to get that test? And other people in the room say, what are you going to do with the information? For those who don't know, Gina Predictor is a test that can be sent on bone marrow. It can be sent on peripheral blood, it can be sent on tumor samples. And it does detailed investigation that includes some information on whether some potential drug targets are expressed. So an example is could the GPRC5D target the target be detected on myeloma cells on the sample that was sent? It can also be used for BCMA expression. And the use cases that I've thought about have been things like, okay, someone had disease relapse after CAR T, is it because they'd no longer produce the target that the CAR T is going after? Couldn't Gina predict a help me know that and make a more thoughtful choice later? Yes, I think it could. But my personal challenges have been that the the time to get the test result back is actually several several weeks. It's pretty extensive. They are still relatively new, so the time to find out that the material submitted for the test wasn't good enough is also several weeks. So sometimes you're waiting for something that's never going to come, and that's that's frustrating. And then I am not good at it. I don't feel fluent enough in reading their reports and understanding what it actually is going to, what I'm going to do with it later on. Thank you. I have two questions. One is, is it called clonoSEQ along with sequence six? Yes, yes. Okay. How do you go about getting that treatment? It has the test. Yes. So if you are to have a bone marrow biopsy done, your treatment team would order the test before they take the bone marrow out of your body. So you remember that I talked about how there's two pieces to the test. The first part is using the historic sample, and the company does a very lovely job of helping to get that historic sample from wherever it's been been stored. So they take care of that part. But for the test that is telling you how much disease is present right now, you need to order that. And then they have to send a sample that is the fresh sample to the lab at the time. So do I have to request that or is that young colleges, the colleges we have to have to place the order. So I have had one done and I've had at least four bone marrow biopsy after and it was not included in. So I think it's worth asking if that was intentional or if it was a mistake. It could be that they did not choose to order the test because they didn't think that it was going to, provide data that they were going to do anything with. And I, I can respect that decision. Like, it's something, you know, I've learned in medical school, but don't order the test. If you don't have a plan for what you're going to do. We don't need to just look at the universe all the time. We should be thinking about what our goals are. So I think it's just worth asking what their what their thought is. Okay, I'll do that. So is it available that multiple myeloma patients will have a relapse? We tell people it is, but I think everybody has a handful of patients that have not relapsed. And we've been pretty gun shy of using the word cure. But I think that in some cases we have achieved cure. Okay. Thank you. Could you say a little bit more about how to interpret the MRD data and the PET scan, and how they balance each other out in decision making? Or you know, what's what's the next steps. Yeah. So the MRD data is. Going to give you a number. So you'll do the test. You get a number back on your report based on what number is there. You'll either be better the same or worse than you were before. So you're definitely comparing to what was done beforehand. And there's then discussion about what you do next, trying to predict where that number is going to go next. The PET scan is a little bit, a little bit less obvious how to interpret in my mind. So the PET scan is Whole body scan, specialized tracer. That's a radiolabeled sugar. Looking to see which tissues are abnormally taking up this sugar. Those are the metabolically active tissues. Some of them are normal. Your brain should be taking up a lot of the sugar. And our reports at OHSU talked about physiologic uptake. And that means normal uptake. And that makes everybody worried when they first read it. So on the PET scan you're wanting to say is there anything that has abnormal uptake if there is something was it an area that had abnormal uptake before? Is it better or worse than what it was before? Is that does that help? Yes. Up is if your PET scan shows no other involvement and a decrease in the original site, but the Mississippi would show a partial, not a complete remission. But we haven't heard, at least as a discussion. It seems like they want to talk, but the PET scan doesn't seem to balance in the equation. So that's just curious to hear your take on. So yes, if the head is good and then all that is measurable is now in the marrow that I think that's that's a very positive thing. I think if the marrow shows that there's no MRD there, but the PET looks like it's worsened, then I think you're asking the question of, is this because the PET was perhaps done too soon to see the the effect of treatment? Or is it because the treatment is not helping the areas that are abnormal on the PET yet so sometimes we do make treatment decisions, treatment changes when the MRD in the marrow is negative. If the PET shows that there's something new that's going on, well, yes, vice versa. Too often, often the PET will sometimes the PET will clean up before the rest of the marrow. The other part, though, to keep in mind, of course, is that the PET isn't going to say it's absolutely myeloma. It's just going to say it's abnormal. And it takes the judgment to say, does it make sense? Is this myeloma, or do we think that this is something else and just do all over the genome project. That I was going to say yes. And. For years I think I don't think we know yet. I the other piece that I don't know is how much difference is the cheetah predictive team seeing in the results that an individual has over time. Because we we acknowledge the fact that in the transition between smoldering myeloma and active, you can have accumulation of of of changes in the genetic material that can include targets, potentially targeted things. So so I don't know how sensitive timeline is for Jena predictive changes as compared to other changes. I'm putting the one year marks. Is it advisable to do the. PET scan combined with MRI or just keep it a bit? It does matter what you had before as far as imaging. So if you had disease. He doesn't want me to say it depends, but it really does depend. If you if you had a completely normal set of imaging before then, I don't know that it is that important. What type of imaging you have at at remission. If you had an MRI or a PET scan that was abnormal before then, I would say maybe you want to get the next test to be the same kind of imaging, so that they can certainly be comparing the same types of pictures with each other. So the suggestion to do the combined MRI and PET is not to get more data, because if it is, I mean that's like the academic answer. Yeah. It's a better it's a it's a it's a it gets you more data, a more complete picture. Correct. Than it would be advisable to do the combination, regardless of whether you've had just the PET scan by itself, I think, yes, intellectually it's advisable. But there's the friction between what we would like to have and what we can actually get. So yes, intellectually, I think it would be great for everybody to get that study. But if it's going to take weeks of writing letters to support the study and a lot of trial and tribulation and hand-wringing and just increased anxiety, I don't know that's necessarily worth it. Unless question. So we will have a question answered later as well. But. Myeloma cells, I guess, tend to stay on the bones. So what is the value of information gained from doing honestly? Testing. It's difficult to know right now. And so that is one of the the pieces that I personally am not sold on using peripheral blood to measure MRD at this point. There are other techniques for measuring disease in the body, in the peripheral blood that aren't necessarily cell based. So we talk about cell-free DNA. There's other ways of seeing if there's myeloma bits that are out there. And so I do think one or several of those techniques is going to end up being very usable for assessing MRD. But I'm not I'm not convinced that is going to be the way to do it. We'll see. Question. For a person who is recently determined to be very based on if you had secretory disease ahead of time, part of it's going to vary as to if you had secretory disease ahead of time. So we talked about how in the majority of patients they are producing protein that can be measured in the blood or the urine. And we use that as our proxy for how much myeloma is active in the body. But there are people who have what's called non-secretory myeloma. And you don't know you just have no way of telling. So if someone has had secretory disease and their labs look perfect and they continue to look perfect and they feel well, I think that honestly, I think that annually is probably pretty good. It also is going to depend on how much you personally hated the bone marrow experience, right? Some people don't ever want to do that again, and they are perfectly content not